This study is being conducted to evaluate the efficacy and safety of SHR-A1811 and Fulvestrant in Combination with or without HS-10352 in locally advanced or metastatic breast cancer patients. Subjects will receive SHR-A1811 and Fulvestrant in Combination with or without HS-10352.
Female patients aged ≥18 years and ≤75 years;
ECOG Performance Status of 0 -2;
Locally advanced/metastatic breast cancer not amenable to curative therapy
Disease progression during treatment or within 12 months of completing adjuvant therapy ;
Breast cancer that has not been histologically confirmed;
Inflammatory breast cancer;
Participants ineligible for endocrine therapy due to any disease burden, as judged by the investigator;
Meningeal metastasis or active parenchymal brain metastasis;